In addition, at 7 days post initiation of therapy and before any change in tumor volume, activated GZMB+ CD8+ T cell number (Fig. 1c) and overall CD8 T cell infiltration into the tumor increased in combination therapy (Fig. 1d and Supplementary Fig. 1B, C). The gene discussed is CD8A; the disease is neoplasm.